Get the Stockscreener App
72.50
4.71%
-3.58
Pre-market:
73.46
0.96
+1.32%
Bio Rad Laboratories Inc stock is traded at $72.50, with a volume of 3.04M.
It is down -4.71% in the last 24 hours and down -14.37% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$76.08
Open:
$75.27
24h Volume:
3.04M
Relative Volume:
2.46
Market Cap:
$14.17B
Revenue:
$579.96M
Net Income/Loss:
$-729.89M
P/E Ratio:
-19.35
EPS:
-3.7459
Net Cash Flow:
$-452.02M
1W Performance:
-3.86%
1M Performance:
-14.37%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$72.12
$75.50
1-Week Range:
$72.12
$76.81
52-Week Range:
$72.12
$89.49
Bio Rad Laboratories Inc Stock (BBIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO
Compare BBIO vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bio Rad Laboratories Inc
|
72.50 | 14.17B | 579.96M | -729.89M | -452.02M | -3.7459 |
ABT
Abbott Laboratories
|
103.36 | 178.85B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.62 | 117.19B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.01 | 103.57B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.10 | 62.46B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.77 | 50.01B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BBIO) Latest News
BIO-RAD LABORATORIES (NYSE: BIO) Grants 719 Derivative Securities to Director Allison Schwartz - Kalkine Media
BIO-RAD LABORATORIES Executive Evran Sedat Reports Exercising 3,880 Shares (NYSE: BIO) - Kalkine Media
Bio-Rad: Favorable Read-Across From Investor Event (NYSE:BIO) - Seeking Alpha
Bio-Rad (NYSE: BIO) director sees 320 RSUs convert, 116 shares withheld - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
Bio-Rad (NYSE: BIO) EVP logs 4,313 RSU grant and 2,179 vested shares - Stock Titan
1,453 stock units vest for Bio-Rad (NYSE: BIO) insider as 551 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) grants EVP 4,601 RSUs, with shares withheld at $386.11 - Stock Titan
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com Canada
Bio-Rad Terminates Forbes Tate Lobbying Pact - legis1.com
Bio-Rad expands range of Foresight prepacked chromatography columns for biomanufacturing - selectscience.net
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating Current Market Challenges with Strategic Insights - DirectorsTalk Interviews
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
BIO-RAD (NYSE: BIO) Director Allison Schwartz Reports 1,573 Shares Following Option Exercise - Kalkine Media
Mesa Laboratories Inc. (MLAB) Peer Comparison – Compare with Others - Value Research
RSU vesting gives Bio-Rad (NYSE: BIO) exec 425 shares - Stock Titan
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Bio-Rad expands Foresight Pro prepacked chromatography columns with Nuvia ion exchange and mixed-mode resins - manufacturingchemist.com
Allied Healthcare Products Inc. (AHPI) Peer Comparison – Compare with Others - Value Research
Bio-Rad Laboratories (BIO) 10K Form and Latest SEC Filings 2026 - MarketBeat
Best Practices for qPCR Assay Design and Optimization - the-scientist.com
Bio-Rad expands Foresight Pro Prepacked Chromatography Columns with Nuvia Ion Exchange and Mixed-Mode Resins for Biomanufacturing - Cambridge Network
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference - Investing News Network
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a Challenging Market with a -15.14% Potential Downside - DirectorsTalk Interviews
Discipline and Rules-Based Execution in BIO Response - Stock Traders Daily
Bio-Rad Laboratories Inc. Class A (BIO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Bio-Rad Laboratories stock hits 52-week high at 394.22 USD - Investing.com Nigeria
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating the Upside Amidst Market Challenges - directorstalkinterviews.com
Why Bio-Rad Laboratories (BIO) Is Up 6.7% After Restructuring Move Amid Mixed Segment Trends - Sahm
Return on invested capital % of Bio-Rad Laboratories, Inc. Class A – HAM:BUWA - TradingView
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation? - Yahoo Finance
Bio-Rad (BIO) Quarter in Focus: Profit Per Share Clears Its Benchmark for the Current Session - vinanet.vn
Bio-Rad Laboratories Inc (BIO) Shares Surge 3.4% -- What GF Scor - GuruFocus
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building? - Yahoo Finance
Westport Asset Management Inc. Invests $881,000 in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories stock hits 52-week high at $365.68 By Investing.com - Investing.com Nigeria
Bio-Rad Laboratories (NYSE:BIO) Reaches New 12-Month HighShould You Buy? - MarketBeat
Bio-Rad Laboratories stock hits 52-week high at $365.68 - Investing.com
Bio Rad Laboratories Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
S&P 500 Futures Decline In Premarket Trading; Bio-Rad Labs A, Fabrinet Lag - Moomoo
Sickle Cell Anemia Testing & Screening Industry Trends & Growth - SNS Insider
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a Challenging Market with Innovative Diagnostics - DirectorsTalk Interviews
BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher. - The Motley Fool
Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost? - Yahoo Finance
Bio-Rad Laboratories (NYSE:BIO) Upgraded to Hold at Zacks Research - MarketBeat
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
First Trust Advisors LP Has $424,000 Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock forecasts - Yahoo Finance UK
Bio Rad Laboratories (BIO) Issues Flat Revenue Guidance, Is It Too Far Above Fair Value? - Sahm
Bio Rad Laboratories Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.29%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):